The Boston-area biotech hasn’t released any data over the last four weeks, but it still was able to pull off a stock sale ...
Bessemer survey of 226 healthcare execs finds AI paying back 3.5x in about a year, with half of respondents cutting staff.
Utah's AI sandbox lets Nolla Health use AI to prescribe acne treatments. Grindr buys Freddie for $250M. Included Health ...
A high 240 mg dose of ArriVent's firmonertinib kept cancer at bay for a median of 11.0 months, compared with chemotherapy at ...
Leerink's David Risinger downgrades Bristol Myers to market perform and cuts his price target to $59, citing doubts on ...
Lycia Therapeutics files for IPO to advance LYTAC degraders as TRexBio targets $111M and Retension $34M in Nasdaq debuts.
Deisseroth, Hegemann and Nagel win the 2026 Nobel in medicine for optogenetics, the basis of Nanoscope's RP gene therapy ...
Epicrispr's epigenetic editor EPI-321 shows a 3% gain in muscle volume in FSHD patients at 6 months, alongside one case of ...
Vaxcyte's shares jumped 35% Monday morning after the company announced that its experimental pneumococcal vaccine VAX-31 met its key endpoints in a Phase 3 trial with adults, a major step in its quest ...
Alector licenses Parkinson's drug AL050 to Roche for $100M upfront and up to $1.17B in milestones, shares up 20%+.
Welcome back to another edition of Endpoints Weekly! It’s October 3rd, the day he asked me what day it was. “It’s October 3rd ...
Kallyope is rebranding as TriGemX Bio as it focuses solely on treating migraine. It also exclusively told Endpoints News that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results